CHPF

Across TCGA pan-cancer cohorts, CHPF RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated CHPF data layer compared with 7 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CHPF RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CHPF expression acts as an unfavorable survival marker, although some lineages such as UVM and THCA show a favorable association.

BRCA, HNSC, and LGG are the cancer types where CHPF RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.484	0.628	<.001	77	view →
HNSC	DFS	Tertile	All	0.661	0.806	<.001	71	view →
LGG	DFS	Median	All	0.650	0.826	<.001	47	view →
BLCA	OS	Quartile	II,III,IV	0.507	0.657	.006	46	view →
UVM	DFS	Quartile	III,IV	0.901	0.172	<.001	39	view →
LUAD	DFS	Tertile	All	0.721	0.836	.002	36	view →
CESC	DFS	Median	All	0.652	0.819	<.001	34	view →
COAD	DFS	Tertile	All	0.700	0.829	.001	30	view →
KIRP	DFS	Median	IV	0.039	0.526	.027	30	view →
LUSC	DFS	Tertile	III,IV	0.164	0.538	.006	21	view →
ACC	DFS	Median	All	0.345	0.638	.028	19	view →
UCS	OS	Median	IV	0.232	0.723	.028	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

CHPF–BRCA (OS)

Open the BRCA breakdown →